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Abstract
Background: Signal transducer and activator of transcription 3 (STAT3) is usually constitutively
activated in a variety of malignancies. Therefore, STAT3 may be a promising target for treatment
of tumor cells. To explore the possibility of a double-stranded decoy oligodeoxynucleotide (ODN)
targeted blocking STAT3 over-activated tumor cells, we, here, evaluate the efficacy of STAT3
decoy ODN on human lung cancer cells in vitro and in vivo.
Methods: A STAT3 decoy ODN was transfected into A549 lung cancer cell line in vitro by using
lipofectamine. The flow cytometry and fluorescent microscopy were used to detect the
transfection efficiency and the sub-cellular localization of STAT3 decoy ODN in A549 cells. Cell
proliferation was determined by counting cell numbers and [3H]-thymidine uptake. Cell apoptosis
was examined with Annexin V and propidum iodide by flow cytometry. The expression levels of
STAT3 target genes were identified by RT-PCR and immunoblot. For in vivo experiment, A549 lung
carcinoma-nude mice xenograft was used as a model to examine the effect of the STAT3 decoy by
intratumoral injection. At the end of treatment, TUNEL and immunohistochemistry were used to
examine the apoptosis and the expression levels of bcl-xl and cyclin D1 in tumor tissues.
Results: STAT3 decoy ODN was effectively transfected into A549 lung cancer cells and mainly
located in nucleus. STAT3-decoy ODN significantly induced apoptosis and reduced [3H]-thymidine
incorporation of A549 cells as well as down-regulated STAT3-target genes in vitro. STAT3 decoy
ODN also dramatically inhibited the lung tumor growth in xenografted nude mice and decreased
gene expression of bcl-xl and cyclin D1.
Conclusion: STAT3 decoy ODN significantly suppressed lung cancer cells in vitro and in vivo,
indicating that STAT3 decoy ODN may be a potential therapeutic approach for treatment of lung
cancer.
Background
The signal transducers and activators of transcription 3
(STAT3), a member of a transcription factor family of
seven proteins (STAT1, 2, 3, 4, 5a, 5b, and 6), plays impor-
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tant roles in regulating cell growth, differentiation, apop-
tosis, angiogenesis, and immune responses [1,2]. STAT3
transduces extracellular signals made by numerous
cytokines and growth factors to nucleus and directly regu-
late gene transcription [3]. Cytokines (e.g. interleukin-6)
and growth factors (e.g. epidermal growth factor) may
bind to their cognate receptors and then activate tyrosine
kinases, which phosphorylates the tyrosine residue of
STAT3. Upon activation, STAT3 dimers translocate into
the nucleus, where they bind to STAT3 specific DNA
response elements and activate their transcription [4,5].
Dysregulation and constitutive activation of STAT3 have
been found in numerous primary cancers such as lympho-
mas, leukemias, multiple myelomas, prostate, breast,
lung, head and neck, melanoma, pancreas, ovary and gas-
tric cancer cells [6-16]. Lung cancer is the leading cause of
death in cancer in the United States. In 2006, an estimated
174,470 new cases, accounting for about 12% of cancer
diagnoses and an estimated 162,460 deaths, accounting
for about 29% of all cancer deaths, are expected to occur
(The American Cancer Society). Constitutive activation of
STAT3 correlates with cell proliferation in non-small-cell
lung cancer (NSCLC) and also inhibits apoptosis [11,17].
Restoration of suppressors of cytokine signalling-3
(SOCS-3), which is frequently silenced by hypermethyla-
tion in lung cancer cells, resulted in the down-regulation
of activated STAT3, leading to induction of apoptosis and
growth suppression [18].
The constantly activated STAT3 contributes to oncogene-
sis by up-regulation of genes encoding bcl-xl, bcl-2, c-myc,
cyclin D1, survivin, mcl-1 [7,8,16,19], and VEGF, IL-10,
TGF-β et al [20-22], which can protect apoptosis, enhance
cell proliferation, promote angiogenesis and evade
immune surveillance [1]. Though there are multiple onco-
genic signaling pathways in each individual tumor, block-
ade of STAT3 signaling is often sufficient to induce growth
arrest and apoptosis in many different tumors [8-12,16].
Therefore, the association of STAT3 activation with tumor
progression suggests that STAT3 may be an attractive
molecular target for cancer therapy.
Many methods to block STAT3 activation were developed
including RNA antisense, RNA interference (RNAi) and
dominant negative mutants [9,23,24]. A double-stranded
decoy oligodeoxynucleotide (dsODN) against transcrip-
tion factor [25] is based on the competition between the
endogenous cis-elements within the regulatory regions of
target genes and the exogenously added molecules mim-
icking the specific cis-elements [26]. Transfection of
dsODN will result in the attenuation of the authentic
interactions of STAT3 with their cis-elements and subse-
quent alteration of gene expression. This strategy has been
successfully used for inhibition of STAT3 in head and neck
cancer and also for inactivation of STAT6 in shifting IL-4-
driven Th2 cell activity [27,28]. Recently, we have found
that STAT3 decoy ODN could inhibit cell growth of a pul-
monary giant cell carcinoma cell line PG in vitro [29].
In the present study, we demonstrate that STAT3 decoy
ODN can suppress lung cancer cells in vitro and in vivo by
efficiently blocking STAT3 signaling, suggesting the thera-
peutic potential of STAT3 decoy ODN in treatment of
human lung carcinoma.
Methods
Cell line and cell culture
The human non-small-cell-lung cancer line, A549, were
grown in RPMI 1640 medium (GIBCO/BRL) supple-
mented with 10% fetal bovine serum (FBS), 100 IU/ml
Table 1: RT-PCR primers for STAT3 target genes
genes Primer sequences Ta Product size
β-actin 5'-CTC CTT AAT GTC ACG CAC GAT TT-3' 56°C 539 bp
5'-GTG GGG CGC CCC AGG CAC CA-3'
cyclin D1 5'-GAG ACC ATC CCC CTG ACG GC-3' 58°C 484 bp
5'-CTC TTC CTC CTC CTC GGC GGC-3'
bcl-xl 5'-GGA AAG CGT AGA CAA GGA GAT GC-3' 55°C 236 bp
5'-GGT GGG AGG GTA GAG TGG ATG GT-3'
c-myc 5'-GGT CTT CCC CTA CCC TCT CAA CGA-3' 55°C 386 bp
5'-GGC AGC AGG ATA GTC CTT CCG AGT-3'
mcl-1 5'-GTG GTG GTG GTG GTT GGT TA-3' 54.5°C 575 bp
5'-CGG CAG TCG CTG GAG ATT AT-3'
survivin 5'-GCA TGG GTG CCC CGA CGT TG-3' 55°C 446 bp
5'-GCT CCG GCC AGA GGC CTC AA-3'
cyclinE 5'-ATA CAG ACC CAC AGA GAC AG-3' 54.5°C 301 bp
5'-TGC CAT CCA CAG AAA TAC TT-3'
Reprinted with permission from Oncology Reports [29].BMC Cancer 2007, 7:149 http://www.biomedcentral.com/1471-2407/7/149
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penicillin and 100 µg/ml streptomycin in 5% CO2 at
37°C.
Antibodies and reagents
Anti-STAT3, anti-phospho-specific STAT3 (Tyr705,
Ser727), anti-bcl-xl, anti-cyclinD1, anti-β-actin antibodies
and horseradish peroxidase-conjugated second antibody
were purchased from Cell Signaling Technology (New
England BioLabs Inc.). Annexin V-FITC was obtained
from BD Biosciences (BD PharMingen, San Diego, CA).
STAT3 decoy and scramble ODN
Phosphorothioated sense and antisense strands of STAT3
decoy or scramble ODNs were synthesized by Expedite™
Nucletic Acid Synthesis System (TaKaRa Biotechnology,
Dalian). The STAT3 decoy ODN sequence was 5'-CATT-
TCCCGTAAATC-3', 3'-GTAAAGGGCATTTAG-5' and the
scramble ODN sequence was 5'-CATCTTGCCAATATC-3',
3'-GTAGAACGGTTATAG-5' [27,30]. The sense and anti-
sense strands were annealed and purified by HPLC.
Transfection of ODN
Transfections were carried out by lipofectamine 2000
(Invitrogen life technologies, Carlsbad, CA) according to
the manufacturer's instructions. Briefly, cells were seeded
at a density of 7 × 103 cells/well (400 µl) in 48 well plates
(Costar, Corning, NY) for 24 h. After washing once with
PBS, cells were transfected with lipofectamine 2000/con-
trol, lipofectamine 2000/decoy ODN, or lipofectamine
STAT3 was constitutively activated in A549 human lung cancer cell line and the efficiency of STAT3 decoy ODN transfected  into A549 cells Figure 1
STAT3 was constitutively activated in A549 human lung cancer cell line and the efficiency of STAT3 decoy 
ODN transfected into A549 cells. (A) The A549 lung cancer cells were lysed in lysing buffer and the whole cell extracts 
(30 µg/lane) were separated by SDS-PAGE and then examined by western blotting using anti-STAT3, anti-phospho-specific 
STAT3 (Tyr 705, Ser727) or β-actin antibodies. The proteins were then detected by the enhanced chemiluminescence (ECL) 
system by exposing to X-ray film. (B) A549 cells were transfected with FITC-labeled STAT3 decoy ODN at final concentration 
of 12.5, 25 and 50 nmol/L in presence of lipofectamine 2000. After transfected for 6 h, the cells were examined by flow cytom-
etry. (C) After transfected with 25 nmol/L FITC-labeled STAT3-ODN for 6 h, the cells were fixed, permeabilizated and stained 
with DAPI, and then fluorescent microscopy was used to observe the nucleus location of ODN. STAT3 decoy ODN (green) 
and nuclei (blue) were overlaid with their contrast image.
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2000/scramble ODN complexes. The final concentration
of ODN was 50, 25 and 12.5 nmol/L separately.
Flow cytometry and fluorescent microscope
The decoy and scramble ODN were labeled with FITC at
5' of ODNs (TaKaRa Biotechnology, Dalian). After trans-
fection of FITC-ODN, cells were detached, washed with
PBS extensively and detected by flow cytometry (FACSCal-
ibur, BD Biosciences, CA). For ODN location analysis,
transfected cells were washed three times, fixed and per-
meabilized, nuclei were stained with DAPI (Jingmei Bio-
technologies, China) for 10 min at room temperature.
After washing, the cells were observed under a fluorescent
microscope.
Cell proliferation assay
Cells were plated and transfected with decoy or scramble
ODN as described above. Cell number was determined by
counting with a hemocytometer using trypan blue exclu-
sion. Above 90% viability was regarded as no toxicity. Cell
proliferation was examined by measuring DNA synthesis
using tritiated thymidine (3H-dThd) uptake. Before trans-
Inhibitory effect of STAT3 decoy ODN on A549 lung cancer cells in vitro Figure 2
Inhibitory effect of STAT3 decoy ODN on A549 lung cancer cells in vitro. (A) A549 cells were seeded at a density of 
1 × 104 cells per well in 48 well plates. After 24 h, the cells were treated with 25 nmol/L STAT3 decoy ODN, STAT3 scramble 
ODN or vehicle control (TE) for different time using lipofectamine 2000. The cumulative number of cells was accounted using 
trypan blue exclusion. Values are expressed as mean ± SD of three independent experiments. (B) A549 cells (4 × 104/well) 
were treated with STAT3 decoy ODN or scramble decoy ODN for 18 hours at 37°C, and then pulsed with [3H]-thymidine for 
an additional 6 hours. The incorporation of [3H]-thymidine was analyzed by liquid scintillation counting. (C) A549 cells were 
plated in six well plate, after transfected with 25 nmol/L STAT3 decoy ODN or scramble ODN, the apoptotic A549 cells were 
detected by flow cytometry using Annexin V-FITC and PI. The histogram represented the percentage of apoptotic cells. Values 
are expressed as the mean ± SD of three independent experiments. Statistical significance was determined as *p < 0.01 com-
pared to other groups.
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fection, cells (4 × 104/well) were cultured in a 24-well
plate in growth media for 24 h. STAT3 decoy or scramble
ODN were transfected for 18 h separately, and then
pulsed for the remaining 6 h with [3H]-thymidine (3.75
µCi/ml). [3H]-thymidine incorporation was analyzed by
liquid scintillation counting.
Cell apoptosis assay
Twelve hours after transfection of 25 nmol/L STAT3 decoy
or scramble ODN, cells were detached, washed and resus-
pended in 100 µl Annexin V binding buffer, and subse-
quently stained with Annexin V-FITC and propidum
iodide (Sigma) according to the manufacturer's recom-
mendation. Data acquisition and analysis were performed
by a flow cytometry using CellQuest software.
Isolation of Total RNA and reverse transcription (RT)-
polymerase chain reaction (PCR)
RT-PCR was performed as previously described [31].
Briefly, total RNA was isolated using TRIzol (Invitrogen,
Carlsbad, CA) and subjected for reverse transcription
using M-MLV Reverse Transcriptase (Invitrogen, Carlsbad,
CA) according to the manufacturer's instructions. cDNAs
were then amplified with the corresponding gene-specific
primers which synthesized by Shanghai Genecore Bio-
technologies (Shanghai, China)(table 1). The PCR prod-
Inhibitory effect of STAT3-decoy-ODN on A549 tumor – bearing nude mice Figure 3
Inhibitory effect of STAT3-decoy-ODN on A549 tumor – bearing nude mice. (A) Human A549 tumor-bearing nude 
mice were established as described in materials and methods. The mice were intratumorally injected daily with STAT3 decoy 
ODN (25 µg), scramble ODN (25 µg) or vehicle control (25 µl PBS) for total thirty injections, and the tumor volumes were 
measured at the indicated day. *p < 0.01 versus PBS treatment control. (B) After daily intratumoral injection of 25 µg STAT3 
decoy ODN for thirty times, the xenografts were collected, sectioned and stained for apoptotic cells by TUNEL which per-
formed as described in materials and methods. The brown stain represented the DNA fragmentation of apoptotic cells and the 
blue showed the nuclei stain with hematoxylin (original magnification ×400). The cumulative results showed the average 
number of apoptotic cells per High Power Field. **p < 0.001 versus PBS treatment control.
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ucts were electrophoresed and photographed using
AlphaEaseFC. The bands were examined by densitometry
using AlphaEaseFC software with normalization of each
band to their corresponding loading control.
Western blot
Sodium dodecyl sulfate polyacrylamide gel electrophore-
sis (SDS-PAGE) and immunoblotting were processed as
described previously [31]. Briefly, the whole cells were
lysed in lysing buffer after transfected with STAT3 decoy
ODN for 24 h. The whole cell extracts (30 µg/lane) were
separated by SDS-PAGE and transferred to nitrocellulose
membrane. After blocked in Tris-buffered saline with 5%
(w/v) nonfat dry milk, membranes were incubated with
primary antibodies (1:1000 dilution) according to the
manufacturer's instructions and then incubated with
horseradish peroxidase conjugated secondary antibody.
The proteins were detected by the enhanced chemilumi-
nescence (ECL) system (Pierce, Rockford, IL) using X-ray
film. The bands were examined by densitometry using
AlphaEaseFC software (Version 4.0.0, Alpha Innotech
Corporation) with normalization of each band to their
corresponding loading control.
Human tumor-bearing nude mouse
Female athymic nude mice (Balb-nu/nu, 4 weeks old,
weighing 18 ± 2 g) were purchased from the Shanghai
Experimental Animal Center (Chinese Academy of Sci-
ences, Shanghai), and maintained at an animal facility
under pathogen-free conditions. The handling of mice
and experimental procedures were conducted in accord-
ance with experimental animal guidelines. A549 cells
were harvested and re-suspended in RPMI 1640 media. 8
× 106 cells (150 µl) were injected into the right flank of the
mice subcutaneously. About 7 days later, when the
tumors reached about 35 mm3, the mice were randomly
assigned to three groups with six mice in each group (PBS
treatment control, STAT3 scramble ODN treatment con-
trol and STAT3 decoy ODN treatment group). ODN (25
µg in 25 µl PBS) was intratumorally injected every day for
totally 30 days. During this period, the tumor volume was
determined by measuring the length (l) and the width (w)
every 5 days, and calculated by using the function (V = l
w2/2).
Terminal Deoxynucleotidyl Transferase-mediated Nick 
End Labeling (TUNEL)
A549 xenografts were collected on the termination day of
antitumor experiment, sectioned and stained for apop-
totic cells by TUNEL using the In Situ Cell Death Detec-
tion Kit, POD (Roche Applied Science, Germany)
according to manufacturer's guides. Briefly, frozen sec-
tions were fixed in 4% paraformaldehyde, incubated in
blocking solution and in permeabilisation solution, and
incubated in TUNEL reaction mixture for 60 min at 37°C.
After rinsing, the sections were incubated with Converter-
POD for 30 min at 37°C and developed with DAB Sub-
state Kit (Boster, Wuhan). The slides were lightly counter-
stained with hematoxylin and then dehydrated and
mounted. For each group, 4 samples were evaluated and
5–10 fields of view were quantitated on each section. The
number of apoptotic cells per high power field (HPF) was
counted.
Immunohistochemistry
The immunohistochemical staining was performed using
peroxidase labeled streptavidin-biotin method (Histo-
stain plus kits, ZYMED, CA) according to the manufac-
turer's protocol. Briefly, five-µm frozen sections were fixed
in acetone. Endogenous peroxidase was blocked by 3%
hydrogen peroxide. After blocked with normal goat
serum, diluted bcl-xl and cyclin D1 primary antibodies (at
a dilution of 1:300) were added to completely cover tissue
and incubated in humidified chamber overnight at 4°C,
and then incubated with biotinylated second antibody,
and finally incubated with streptavidin-peroxidase conju-
gate (S-A/HRP). The immune complex was visualized
with 3, 3-diaminobenzidine (DAB substate kit, Boster,
Wuhan). The slides were lightly counterstained with
hematoxylin and then dehydrated and mounted. As nega-
tive controls, rabbit immunoglobulin was used to replace
primary antibody.
Statistical analysis
Statistical analysis was performed with SPSS software (ver-
sion 10.0, SPSS Inc). Data were presented as mean ± SD. p
< 0.05 were considered statistically significant.
Results
STAT3 was constitutively activated in A549 human lung 
cancer cell line and STAT3 decoy ODN was efficiently 
transfected into A549 cell lines
To examine whether STAT3 is persistently activated in
human lung cancer cells, the whole cell lysate from the
human non-small-cell-lung carcinoma line A549 was
processed for western blotting with anit-STAT3 and anti-
phospho-specific STAT3 (Tyr705, Ser727) antibodies. As
shown in Fig. 1A, STAT3 was phosphorylated on Tyr705
and Ser727 in A549 lung cancer cells, which was consist-
ent with our previous observation in human pulmonary
giant cell carcinoma cell line PG [29]. These data demon-
strated that STAT3 was constitutively activated in human
lung cancer cells.
To assay the transfection efficiency of decoy ODN into
cells, we used a FITC-labeled decoy ODN to verify
whether the decoy ODN could be introduced into A549
cells. The results measured by a flow cytometry showed
the decoy ODN could be efficiently transfected into A549
cells with a dose-dependent manner after incubating for 6BMC Cancer 2007, 7:149 http://www.biomedcentral.com/1471-2407/7/149
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h (Fig. 1B). The transfection efficiency was 93%, and the
mean fluorescence intensity (MFI) was 53.36 at 25 nmol/
L, and 92.31 at 50 nmol/L of ODN, respectively. Similar
results were observed with scramble ODN. Moreover, the
sub-cellular localization of decoy ODN was determined
by a fluorescent microscopy. As shown in Fig. 1C, most of
decoy ODN were located in nucleus. These data indicated
that decoy ODN could be efficiently transfected into cells
and located in the nucleus.
STAT3 decoy ODN inhibited the growth of A549 cells in 
vitro
Since cancer is now viewed not only as being the conse-
quence of uncontrolled proliferation, but also as the result
of an altered balance between cell proliferation and rate of
apoptosis, we examined the effects of STAT3 decoy ODN
on cell proliferation and apoptosis of lung cancer cells.
A549 cells were transfected with STAT3 decoy ODN or
scramble control ODN. As present in Fig. 2A, the total
amount of A549 cells was significantly reduced by STAT3
decoy ODN (25 nmol/L) with maximum inhibition rate
of 63.45% (p < 0.01). STAT3 decoy ODN also markedly
suppressed the incorporation of [3H]-thymidine (65.9%)
if compared with the control cells (Fig. 2B). In contrast,
the scramble did not inhibit the growth of human lung
cancer cells. Cell apoptosis was also examined with
Annexin V and PI by flow cytometry after cells transfected
with STAT3 decoy ODN. Compared with scramble ODN,
STAT3 decoy ODN decreased the expression of STAT3-regulated cell growth or anti-apoptotic genes Figure 4
STAT3 decoy ODN decreased the expression of STAT3-regulated cell growth or anti-apoptotic genes. (A) 
After transfected with 25 nmol/L STAT3 decoy ODN or scramble ODN for 24 h, the whole A549 cells were harvested and 
the total cellular RNA was isolated using Trizol Reagent, mRNA levels of STAT3-correlated genes such as mcl-1, cyclin D1, bcl-
xl, cyclinE, c-myc and survivin were detected using RT-PCR method. The PCR products were electrophoresed and photo-
graphed using AlphaEaseFC. (B) After transfected with 25 nmol/L decoy ODN, the whole A549 were harvested and the 
whole-cell extracts were obtained. And western blotting for bcl-x1 and cyclin D1 were then examined as described in materi-
als and methods. Histogram presented the relative expression level of each gene or protein after normalization to its corre-
sponding internal control. Statistical significance was determined as *p < 0.01 and #p < 0.05 compared to control.
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STAT3 decoy ODN could significantly induce apoptosis
from 11.73% to 29.05% (Fig. 2C, p < 0.01). These find-
ings suggest the STAT3 decoy effectively inhibits the cell
growth by reducing proliferation or/and inducing apopto-
sis of lung carcinoma cells.
STAT3 decoy ODN inhibited tumor growth and increased 
apoptosis in xenografts
The in vivo efficacy of STAT3 decoy ODN was tested using
nude mice bearing human A549 lung carcinoma
xenografts. When the tumors were established, the mice
were randomly assigned and treated with STAT3 decoy or
scramble ODN (intratumoral injection daily). The tumor
growth curves were shown in Fig. 3A. After approximately
30 days, the tumor volume in PBS control group increased
to 639 ± 43 mm3, whereas the tumor volume in STAT3
decoy ODN treatment group was only 195 ± 24 mm3,
indicating that the tumor growth was inhibited by 69.5%
(p < 0.01). TUNEL was also used to examine the apoptotic
tumor cells after STAT3 decoy ODN treatment in vivo. As
shown in Fig. 3B, the number of TUNEL positive cells in
tumor tissues treated with STAT3 decoy ODN was signifi-
cantly greater than that treated with vehicle or scramble
ODN. Compared with PBS treatment group, the apoptotic
cells in STAT3 decoy ODN treatment group were
increased by about 20 folds (p < 0.001). These results indi-
cate that STAT3 decoy ODN is effective in reducing tumor
growth and inducing apoptosis of lung tumor cells in
mice.
STAT3 decoy ODN decreased the expression of bcl-xl and cyclin D1 in xenografts by Immunohistochemical analysis Figure 5
STAT3 decoy ODN decreased the expression of bcl-xl and cyclin D1 in xenografts by Immunohistochemical 
analysis. The harvested xenografts which treated with decoy or scramble ODN were sectioned and performed immunohisto-
chemical analysis of bcl-xl (A) and cyclin D1 (B) as described in materials and methods. The brown showed the expression lev-
els of bcl-xl and cycln D1; the blue showed the nuclei (original magnification ×400). Each histogram presented the number of 
bcl-xl and cyclin D1 positive cells per High Power Field in tumor tissues. Statistical significance was determined as #p < 0.05.
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STAT3 decoy ODN decreased the expression of STAT3-
regulated cell growth or anti-apoptotic genes of lung 
cancer cells in culture
To investigate whether the inhibitory effect of STAT3
decoy ODN on lung carcinoma cells is correlated with
expression of STAT3-target genes, RT-PCR was used to
detect the mRNA levels of STAT3 target genes such as cell
cycle genes cyclin D1 and cyclin E, or apoptosis regulating
genes mcl-1 and bcl-xl. As illustrated in Fig. 4A, the mRNA
levels of mcl-1, cyclin D1, bcl-xl and cyclin E were
decreased by 57.1%, 52.3%, 69.5% and 50%, respectively
(p < 0.01), however, the transcription of c-myc and sur-
vivin did not show obvious changes. By contrast, scramble
ODN showed no effect on the transcription of the cancer
cells. Since cyclin D1 and bcl-xl are thought to be the
downstream proteins of activated STAT3 [19], which
greatly contributes to tumor progression, we then exam-
ined the expression levels of these two proteins by western
blot. Compared with control, the expression levels of bcl-
xl and cyclin D1 in A549 cells were attenuated by 37.4%
(p < 0.05) and 60.7% (p < 0.01), respectively (Fig. 4B).
These data suggest that blockade of the expression of
STAT3-drived cell growth and apoptosis-related genes
may be involved in the inhibition of STAT3 decoy ODN
on growth of human lung cancer cells in culture.
STAT3 decoy ODN decreased the expression of bcl-xl and 
cyclin D1 in xenografts by Immunohistochemical analysis
To evaluate effect of STAT3 decoy ODN on gene expres-
sion in nude mice with A549-derived xenografts, immu-
nohistochemical analysis was practiced to determine the
expression of bcl-xl and cyclin D1 in tumor tissues. The
intensity of brown stain corresponds to the expression lev-
els of bcl-xl (Fig. 5A) and cyclin D1 (Fig. 5B). The level of
bcl-xl and cyclin D1 was lower in STAT3 decoy ODN-
treated tumor-bearing mice compared with that in vehicle
control or scramble control (p < 0.05). These observations
on tumor tissues from in vivo xenografts were consistent
with the data obtained from in culture experiments (Fig.
4A &4B).
Discussion
Cumulative evidence support that STAT3 activation and
the novel decoy ODN approach may be used as an antitu-
mor strategy. Unlike in normal cells and tissues, the con-
stitutively activated STAT3 has been observed in a wide
variety of human cancer cell lines and primary tumors.
Therefore, STAT3 has also been recognized as an onco-
gene [2,19]. By using the specific antibody against phos-
phorylated STAT3 and western blot, we, here, show that
STAT3 is constitutively activated in A549 human non-
small-cell lung cancer cell line (Fig. 1A), which was con-
sistent with our previous observations [29] in human pul-
monary giant cell carcinoma PG cell line. These results
further support the idea that the activated STAT3 may be
a good molecular target for lung cancer treatment.
Decoy ODNs have been proposed as a useful approach to
block the function of transcription factors. There are sev-
eral attractive advantages of decoy method over the other
gene therapeutic approaches [32,33]. First, decoy ODN, as
a small DNA molecule, can be easily delivered to specific
tissues and transfected into cells, and directly abrogate the
activated transcript factors. Second, a growing number of
transcript factors with their promoter sequences have
been found, which made the potential drug targets plenti-
ful and readily identifiable. Third, the synthesis, storage
and transportation of decoy ODNs are much simpler than
other approaches. Finally, decoy ODNs have been docu-
mented to be more effective than antisense ODN in block-
ing constitutively activated transcript factors [26].
Moreover, the clinical application of decoy ODN against
E2F was approved by the Food and Drug Administration
(FDA) to treat neointimal hyperplasia in vein bypass
grafts. A clinical trial using NF-κB decoy ODN was also
started in Japan, and positive results of phase I/II trial for
the treatment of atopic dermatitis was made in 2006.
In present study, we used STAT3 decoy ODN to turn down
the constitutively activated STAT3 in lung cancer cells. The
results showed that STAT3 decoy ODN significantly
decreased viable cell number by inducing apoptosis and
reducing [3H]-thymidine incorporation of A549 non-
small-cell lung cancer cell line in vitro (Fig. 2), which was
in parallel with our recent findings in a different type of
lung cancer cell line PG [29], suggesting that STAT3 decoy
could effectively suppress cell growth of lung cancer. Since
either cells that are dead or undergoing apoptosis, like
cells that are stuck in G0/G1, may also show reduced [3H]-
thymidine incorporation compared with control cells,
further studies are necessary to clarify what the relative
contributions of apoptosis vs. reduced proliferation are to
the growth inhibition observed in the lung cancer cells.
To confirm the above inhibitory effect of STAT3 decoy
ODN on human lung cancer cells in culture, we used
human A549 lung tumor xenograft mice to assay the in
vivo efficacy of STAT3 decoy ODN. Compared to PBS
vehicle control and scramble control, STAT3 decoy ODN
significantly inhibited the tumor growth (Fig. 3A) in mice
as well as remarkably increased the number of TUNEL-
positive apoptotic cells in xenograft tumor tissues (Fig.
3B). Both in vitro and in vivo experimental results demon-
strated the potential values of STAT3 decoy ODN
approach in the treatment of lung cancer.
We next investigated the molecular mechanisms by which
STAT3 decoy ODN inhibited growth of lung cancer cells.
Blockade of STAT3 signaling by STAT3 decoy ODN couldBMC Cancer 2007, 7:149 http://www.biomedcentral.com/1471-2407/7/149
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down-regulate the cell growth genes (such as cyclin D1) or
anti-apoptotic genes (such as bcl-xl) at both mRNA and
protein levels (Fig.4 &5). Inhibition of STAT3 signalling
resulted in the decreased survivin and c-myc expression in
many tumor cell lines, however, in A549 cells, the tran-
scription levels of survivin and c-myc were not down-reg-
ulated by STAT3 decoy ODN treatment. One of the
reasons was that the expressions of c-myc and survivin
may also be controlled by other transcription factors such
as STAT5 and STAT1, which may compensate it when the
STAT3 was blocked [34,35]. Therefore, the inhibition of
tumor growth by STAT3 decoy ODN was significantly
associated with blockade of the STAT3-regulated cell cycle
and anti-apoptotic proteins.
Conclusion
In summary, we have provided evidence that STAT3 decoy
ODN suppresses growth of lung cancer cells in vitro and in
vivo through affecting the balance between cell prolifera-
tion and rate of apoptosis. This inhibitory effect may be
correlated to blockade of STAT3-regulated cell cycle genes
or anti-apoptotic genes. Our findings highlight that STAT3
may be a good candidate molecular target, and STAT3
decoy ODN may potentially be used as an anti-lung can-
cer therapeutic small bio-molecule.
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